全文获取类型
收费全文 | 18268篇 |
免费 | 1367篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 98篇 |
儿科学 | 564篇 |
妇产科学 | 531篇 |
基础医学 | 2491篇 |
口腔科学 | 322篇 |
临床医学 | 2584篇 |
内科学 | 3331篇 |
皮肤病学 | 385篇 |
神经病学 | 1803篇 |
特种医学 | 350篇 |
外科学 | 1608篇 |
综合类 | 176篇 |
一般理论 | 38篇 |
预防医学 | 2367篇 |
眼科学 | 424篇 |
药学 | 1345篇 |
中国医学 | 43篇 |
肿瘤学 | 1227篇 |
出版年
2024年 | 28篇 |
2023年 | 223篇 |
2022年 | 330篇 |
2021年 | 675篇 |
2020年 | 438篇 |
2019年 | 628篇 |
2018年 | 671篇 |
2017年 | 495篇 |
2016年 | 552篇 |
2015年 | 572篇 |
2014年 | 744篇 |
2013年 | 1055篇 |
2012年 | 1493篇 |
2011年 | 1472篇 |
2010年 | 829篇 |
2009年 | 675篇 |
2008年 | 1130篇 |
2007年 | 1156篇 |
2006年 | 1057篇 |
2005年 | 1050篇 |
2004年 | 922篇 |
2003年 | 878篇 |
2002年 | 733篇 |
2001年 | 103篇 |
2000年 | 72篇 |
1999年 | 95篇 |
1998年 | 145篇 |
1997年 | 125篇 |
1996年 | 111篇 |
1995年 | 95篇 |
1994年 | 83篇 |
1993年 | 94篇 |
1992年 | 54篇 |
1991年 | 49篇 |
1990年 | 39篇 |
1989年 | 30篇 |
1988年 | 41篇 |
1987年 | 41篇 |
1986年 | 34篇 |
1985年 | 37篇 |
1984年 | 46篇 |
1983年 | 44篇 |
1982年 | 48篇 |
1981年 | 45篇 |
1980年 | 53篇 |
1979年 | 22篇 |
1978年 | 32篇 |
1977年 | 29篇 |
1974年 | 20篇 |
1973年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
103.
104.
105.
106.
Elvin A. Kabat C. Phillip Miller Hilda Kaiser Alice Z. Foster 《The Journal of experimental medicine》1945,81(1):1-8
1. The quantitative method for the estimation of agglutinins has been applied to antimeningococcal horse, rabbit, and chicken sera and to the sera of humans convalescing from meningococcus meningitis. The type-specific and group-specific agglutinin N can be measured, using homologous and heterologous suspensions of meningococci. 2. Type I horse, rabbit, and chicken antimeningococcal sera contain considerable amounts of antibody which cannot be removed either by Type II meningococcus suspension or by preparations of the Type I specific polysaccharide. This residual type-specific antibody has marked potency in protecting mice against subsequent infection with meningococci. 3. Most human convalescent sera contain group-specific antibody. Small amounts of protective antibody and of antipolysaccharide are also formed. 4. Type I antisera absorbed with Type I polysaccharide and with Type II meningococci could be used as a guide in the purification of this new antigen. 相似文献
107.
Laura Oggianu Giorgio Di Dato Giorgina Mangano Maria Teresa Rosignoli Savannah McFeely Alice Ban Ke Hannah M. Jones Alessandro Comandini 《CTS Clinical and Translational Science》2022,15(6):1417
Trazodone is approved for the treatment of major depressive disorders, marketed as immediate release (IR), prolonged release, and once a day (OAD) formulation. The different formulations allow different administration schedules and may be useful to facilitate patients’ compliance to the antidepressant treatment. A previously verified physiologically‐based pharmacokinetic model based on in vitro and in vivo information on trazodone pharmacokinetics was applied, aiming at predicting brain receptor occupancy (RO) after single and repeated dosing of the IR formulation and repeated dosing of the OAD formulation in healthy subjects. Receptors included in the simulations were selected using static calculations of RO based on the maximum unbound brain concentration (Cmax,brain,u) of trazodone for each formulation and dosing scheme, resulting in 16 receptors being simulated. Seven receptors were simulated for the IR low dose formulation (30 mg), with similar t onset and duration of coverage (range: 0.09–0.25 h and 2.1–>24 h, respectively) as well as RO (range: 0.64–0.92) predicted between day 1 and day 7 of dosing. The 16 receptors evaluated for the OAD formulation (300 mg) showed high RO (range: 0.97–0.84 for the receptors also covered by the IR formulation and 0.73–0.48 for the remaining) correlating with affinity and similar duration of time above the target threshold to the IR formulation (range: 2–>24 h). The dose‐dependent receptor coverage supports the multimodal activity of trazodone, which may further contribute to its fast antidepressant action and effectiveness in controlling different symptoms in depressed patients. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
108.
109.
Lingbo Wang Michael Crennan Angela Benic Derek Chiu Fiona Morris Denise E. Jackson 《Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie》2022,49(3):180
IntroductionThe Bombay phenotype is a rare blood group determined by the absence of H antigens. Bombay individuals produce anti-H, a clinically significant antibody that react against all ABO blood group. Anti-H can mask underlying alloantibody during antibody investigation, a challenge in current transfusion practice. The aim of this article is to explore saliva inhibition, a novel method to detect underlying alloantibody in Bombay individuals.Case PresentationThe case is a 93-year-old female transfused with pre-donated autologous blood for a surgery. We determined anti-H subclass and thermal amplitude, secretor status, and optimal ratio of saliva and Bombay plasma. Plasma samples containing anti-H were spiked with anti-Fy(a) to determine the effectiveness of saliva inhibition in uncovering underlying alloantibodies.ResultsAnti-H was confirmed to be predominately IgM with broad thermal amplitude. Tube immediate spin (IS) showed stronger anti-H reactivity compared to column agglutination technology (CAT). Spiked anti-Fy(a) was successfully detected using saliva inhibition method.ConclusionTube IS appears more sensitive to anti-H. Saliva inhibition appears to be a promising method to detect underlying alloantibody in the plasma of Bombay phenotype individuals. 相似文献
110.
Daniela Gerges Sebastian Kapps Esperanza Hernndez-Carralero Raimundo Freire Monika Aiad Sophie Schmidt Wolfgang Winnicki Thomas Reiter Sahra Pajenda Alice Schmidt Gere Sunder-Plassmann Ludwig Wagner 《Viruses》2022,14(6)
SARS-CoV-2 variants of concern (VOCs) have caused a significant increase in infections worldwide. Despite high vaccination rates in industrialized countries, the fourth VOC, Omicron, has outpaced the Delta variant and is causing breakthrough infections in individuals with two booster vaccinations. While the magnitude of morbidity and lethality is lower in Omicron, the infection rate and global spread are rapid. Using a specific IgG multipanel-ELISA with the spike protein’s receptor-binding domain (RBD) from recombinant Alpha, Gamma, Delta, and Omicron variants, sera from health-care workers from the Medical University of Vienna were tested pre-pandemic and post-vaccination (BNT162b2; ChAdOx1 nCoV-19). The cohort was continuously monitored by SARS-CoV-2 testing and commercial nucleocapsid IgG ELISA. RBD IgG ELISA showed significantly lower reactivity against the Omicron-RBD compared to the Alpha variant in all individuals (p < 0.001). IgG levels were independent of sex, but were significantly higher in BNT162b2 recipients <45 years of age for Alpha, Gamma, and Delta (p < 0.001; p = 0.040; p = 0.004, respectively). Pre-pandemic cross-reactive anti-Omicron IgG was detected in 31 individuals and was increased 8.78-fold after vaccination, regardless of vaccine type. The low anti-RBD Omicron IgG level could explain the breakthrough infections and their presence could also contribute to a milder COVID-19 course by cross-reactivity and broadening the adaptive immunity. 相似文献